Meeder Asset Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Meeder Asset Management’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-119	Closed	-$1K	–	2705
2021 Q1	$1K	Buy	+119	New	+$2K	﹤0.01%	2282
2020 Q4	–	Sell	-119	Closed	-$2K	–	2282
2020 Q3	$2K	Sell	119 -121	-50%	-$1.81K	﹤0.01%	1887
2020 Q2	$4K	Hold	240	–	–	﹤0.01%	1621
2020 Q1	$2K	Sell	240 -179	-43%	-$2.5K	﹤0.01%	2127
2019 Q4	$10K	Sell	419 -352	-46%	-$5.02K	﹤0.01%	1575
2019 Q3	$11K	Buy	771 +507	+192%	+$7.44K	﹤0.01%	1514
2019 Q2	$4K	Hold	264	–	–	﹤0.01%	1753
2019 Q1	$5K	Hold	264	–	–	﹤0.01%	1414
2018 Q4	$4K	Sell	264 -12	-4%	-$211	﹤0.01%	1477
2018 Q3	$6K	Buy	+276	New	+$8.39K	﹤0.01%	1302
2018 Q2	–	Sell	-20	Closed	-$1K	–	1709
2018 Q1	$1K	Buy	20 +6	+43%	+$425	﹤0.01%	1492
2017 Q4	$1K	Sell	14 -1	-7%	-$83	﹤0.01%	1605
2017 Q3	$1K	Sell	15 -11	-42%	-$844	﹤0.01%	1576
2017 Q2	$2K	Sell	26 -4	-13%	-$495	﹤0.01%	1439
2017 Q1	$7K	Sell	30 -302	-91%	-$43.1K	﹤0.01%	970
2016 Q4	$30K	Buy	+332	New	+$37.4K	﹤0.01%	611

Other funds holding LUMO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Meeder Asset Management's LUMO Position: Q2 2021 in Review

Meeder Asset Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2021, closing a stake of 119 shares — an estimated $1K sold.

Meeder Asset Management first reported a position in LUMO in Q4 2016 and held it in 16 quarters. The position peaked at $30K in Q4 2016. 40 funds tracked by Wall St. Rank hold LUMO as of Q2 2021.

Meeder Asset Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Meeder Asset Management sold 119 Lumos Pharma, Inc. Common Stock shares in Q2 2021, an estimated $1K.
Meeder Asset Management first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2016 and held it in 16 quarters.
Meeder Asset Management's Lumos Pharma, Inc. Common Stock position peaked at $30K in Q4 2016.
40 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2021.

Based on Meeder Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.